{"product_id":"steris-swot-analysis","title":"Steris SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSteris stands at the intersection of healthcare reliability and procedural innovation, leveraging a strong installed base, steady recurring revenue, and regulatory know-how, yet faces margin pressure from raw material costs and competitive sterilization alternatives; uncover how these forces shape its valuation and strategic options. Purchase the full SWOT analysis for a professionally formatted, editable report and Excel matrix to guide investment, M\u0026amp;A, or operational decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Sterilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTERIS leads the global infection-prevention market, owning ~28% share in sterilization equipment sales and serving over 65,000 hospital and lab sites worldwide as of Dec 31, 2025.\u003c\/p\u003e\n\u003cp\u003eIts massive installed base creates high switching costs—clients average 7–10 year equipment lifecycles and recurring service contracts worth ~40% of annual revenue.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 STERIS’s reliability brand and regulatory approvals (FDA, CE) remain primary barriers to new entrants, supporting a stable pricing premium and double-digit service margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Recurring Revenue Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa substantial portion of steris plc revenue comes from consumables service contracts and outsourced sterilization rather than one-time equipment sales with recurring representing about total billion. this subscription- service-heavy mix delivers predictable cash flow helped maintain adjusted ebitda margin near despite softer hospital capital budgets. long-term ties support customer retention steady margins across cycles.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive and Integrated Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTERIS offers a full suite from large sterilization systems to surgical instruments and proprietary chemistries, enabling single-source procurement for hospitals and health systems.\u003c\/p\u003e\n\u003cp\u003eThis integration drives recurring revenue: in fiscal 2024 STERIS reported 68% of sales from consumables and services, keeping customers tied to its ecosystem over equipment lifecycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Regulatory Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTERIS has decades of FDA, EMA, and global medical-device regulatory experience, letting it launch products faster while meeting strict safety standards.\u003c\/p\u003e\n\u003cp\u003eAs of late 2025, STERIS’s MDR adaptation and regulatory pipeline reduced time-to-market by ~15% versus smaller peers; 2024 regulatory-related revenue resilience helped sustain 2025 organic growth near 6%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDecades of FDA\/EMA experience\u003c\/li\u003e\n\u003cli\u003eMDR readiness as of late 2025\u003c\/li\u003e\n\u003cli\u003e~15% faster time-to-market vs smaller peers\u003c\/li\u003e\n\u003cli\u003eSupports ~6% organic growth in 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Research and Development Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTERIS reinvests ~8–10% of revenue into R\u0026amp;D (2024: $214M), speeding sterilization cycles and greener decontamination tech that cut turnover times and chemical waste.\u003c\/p\u003e\n\u003cp\u003eThose innovations raise OR throughput and patient safety—key clinical KPIs—and STERIS’s patents support high-margin launches, backing organic revenue growth (2024 organic growth ~6%).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend 2024: $214M\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D\/rev: ~8–10%\u003c\/li\u003e\n\u003cli\u003e2024 organic growth: ~6%\u003c\/li\u003e\n\u003cli\u003eFaster cycles = higher throughput\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSTERIS: Market-leading sterilizers, $5.3B revenue, 65k sites, ~28% share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTERIS leads infection-prevention with ~28% sterilizer share, 65,000+ sites (Dec 31, 2025), ~66–68% recurring revenue (2024), $5.3B revenue (2024), 2024 adjusted EBITDA ~22%, R\u0026amp;D $214M (8–10% rev), MDR-ready late 2025, ~15% faster time-to-market, ~6% organic growth (2024–25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$5.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring rev\u003c\/td\u003e\n\u003ctd\u003e66–68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled sites\u003c\/td\u003e\n\u003ctd\u003e65,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSterilizer share\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin 2024\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e$214M (8–10%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic growth\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-market vs peers\u003c\/td\u003e\n\u003ctd\u003e~15% faster\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview identifying Steris’s core strengths, internal weaknesses, external opportunities, and market threats to assess its strategic position and future growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise Steris SWOT matrix for rapid alignment of infection‑control strategy and operational priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Dependence on Healthcare Capital Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhile STERIS reports strong recurring revenue—about 62% of 2024 revenue from consumables\/services—its equipment arm still depends on hospitals funding costly upgrades; global hospital capex fell ~3% in 2023 and many systems deferred purchases in 2024. In tightened budgets or reduced public funding, sales cycles for sterilization units can extend from 6–12 months to 18+ months, raising revenue volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt from Strategic Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSteris carried about $6.2 billion in long-term debt after its 2023–2024 acquisition spree, and high US rates of ~5.25% at end-2025 make interest expense a heavy drain on cash flow.\u003c\/p\u003e\n\u003cp\u003eServicing that debt constrains free cash for M\u0026amp;A and R\u0026amp;D, limiting expansion options unless deleveraging occurs.\u003c\/p\u003e\n\u003cp\u003eKeeping the leverage ratio near covenant targets needs strict cash management and asset sales risk; a downgrade would raise borrowing costs further.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration Complexity of Global Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManaging Steris’s large network of subsidiaries and acquisitions across North America, Europe, and Asia creates ongoing cultural and operational integration challenges that raised SG\u0026amp;A margins to 20.4% in FY2024, vs peers at ~17%.\u003c\/p\u003e\n\u003cp\u003eDisparate ERP and supply-chain systems contributed to a 6% inventory-to-revenue ratio in 2024, increasing working-capital needs and causing periodic fulfillment delays.\u003c\/p\u003e\n\u003cp\u003eThese internal complexities slow decision cycles and raised administrative headcount 8% year-over-year in 2024, reducing agility versus more streamlined competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Raw Material Price Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSteris faces margin pressure from raw-material swings: stainless steel and copper rose ~18% and 25% in 2021–2022 supply shocks, and global resin prices jumped ~40% in 2021; inability to pass costs through contract terms could cut gross margins—Steris reported a 2024 adjusted gross margin of ~42%, sensitive to input costs.\u003c\/p\u003e\n\u003cp\u003eElectronic component shortages remain a disruption risk—lead times for chips averaged 20–28 weeks in 2021–2023—adding schedule slips and higher expedite costs that can delay deliveries and raise operating expenses.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh exposure to metals, plastics, chemical precursors\u003c\/li\u003e\n\u003cli\u003eCommodity spikes compress gross margin (2024 adj. GM ~42%)\u003c\/li\u003e\n\u003cli\u003eChip lead-times 20–28 weeks can disrupt production\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Elective Procedure Volumes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa notable share of steris revenue consumables and services sales directly to elective surgical volumes widespread deferrals from staffing shortages or public-health crises can cut short-term by double-digit percentages in affected quarters. this dependence makes quarterly performance sensitive hospital operational capacity external shocks as seen when elective-procedure slowdowns reduced comparable-service localized events.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~42% of consumables\/services tied to elective surgeries\u003c\/li\u003e\n\u003cli\u003eElective deferrals can reduce revenue by ~10%+ in quarters\u003c\/li\u003e\n\u003cli\u003eShort-term results beholden to hospital staffing and public health\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSteris risk spotlight: high debt, elongated sales cycles \u0026amp; elective-surgery exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSteris’ weaknesses: high leverage (~$6.2B LT debt end-2024) raising interest burden with U.S. rates ~5.25% (end-2025); reliance on hospital capex—global hospital capex fell ~3% in 2023—extends sales cycles to 18+ months; supply-chain\/ERP fragmentation lifted SG\u0026amp;A to 20.4% (FY2024) and inventory\/revenue ~6%, while ~42% of consumables sales tie to elective surgeries, exposing revenue to staffing\/public-health shocks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLT debt\u003c\/td\u003e\n\u003ctd\u003e$6.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. gross margin\u003c\/td\u003e\n\u003ctd\u003e~42% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e20.4% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory\/Revenue\u003c\/td\u003e\n\u003ctd\u003e~6% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables tied to electives\u003c\/td\u003e\n\u003ctd\u003e~42% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSteris SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version. You’re viewing a live preview of the actual SWOT analysis file, and the complete, editable document becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752793485689,"sku":"steris-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/steris-swot-analysis.png?v=1772245562","url":"https:\/\/matrixbcg.com\/products\/steris-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}